CytomX Therapeutics, Inc. (CTMX) Stock Analysis — Probabli.AI
AI-powered analysis for CTMX (CytomX Therapeutics, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $4.45 · Market cap: $826.0M · AI outlook: Bullish
CytomX Therapeutics, focusing on innovative oncology treatments, currently represents a high-risk, high-reward investment. Its strong analyst consensus, promising pipeline reports, and strategic partnerships present considerable upside potential, particularly in the mid-to-long-term horizons. However, the competitive and regulatory nature of its field introduces risks that should not be…
Probabilistic 1-Year Outlook
- Bull 45% · Neutral 40% · Bear 15%
- 1-year price estimates — P10: $4 / P50: $7 / P90: $12
- CytomX Therapeutics has strong analyst support, recent positive clinical results, and strategic partnerships. These indicate significant potential upside, albeit investors should remain cautious due to the competitive…
5-Year Outlook
- Bull 60% · Neutral 30% · Bear 10%
- 5-year price estimates — P10: $4 / P50: $17 / P90: $45
SWOT Highlights
- Strength: Innovative cancer therapeutics pipeline
- Strength: Strategic partnerships, including financial backing
- Risk: Negative revenue growth expectations
- Risk: Challenges in commercialization
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
10 Wall Street analysts rate CTMX a BUY with a mean price target of $11.9.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
CTMX forecast details · CTMX sentiment details · CTMX insider activity
Recent saved forecast research
AI-generated research records, not evaluated investment results.
- CytomX Therapeutics, Inc. (CTMX) — saved
CytomX Therapeutics, focusing on innovative oncology treatments, currently represents a high-risk, high-reward investment. Its strong analyst consensus, promising pipeline reports, and strategic partnerships present considerable upside pote
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.